Search

Your search keyword '"de Bont, Eveline S.J.M."' showing total 21 results
Start Over Author "de Bont, Eveline S.J.M." Journal blood
21 results on '"de Bont, Eveline S.J.M."'

3. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

Author

Bachas, Costa, Schuurhuis, Gerrit Jan, Hollink, Iris H.I.M., Kwidama, Zinia J., Goemans, Bianca F., Zwaan, C. Michel, van den Heuvel-Eibrink, Marry M., de Bont, Eveline S.J.M., Reinhardt, Dirk, Creutzig, Ursula, de Haas, Valerie, Assaraf, Yehuda G., Kaspers, Gertjan J.L., and Cloos, Jacqueline

Published
2010
Full Text
View/download PDF

6. RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

Author

Cucchi, David G.J., Denys, Barbara, Kaspers, Gertjan J.L., Janssen, Jeroen J.W.M., Ossenkoppele, Gert J., de Haas, Valérie, Zwaan, C. Michel, van den Heuvel-Eibrink, Marry M., Philippé, Jan, Csikós, Tamás, Kwidama, Zinia, de Moerloose, Barbara, de Bont, Eveline S.J.M., Lissenberg-Witte, Birgit I., Zweegman, Sonja, Verwer, Femke, Vandepoele, Karl, Schuurhuis, Gerrit Jan, Sonneveld, Edwin, and Cloos, Jacqueline

Published
2018
Full Text
View/download PDF

7. Impact of Additional Cytogenetic Abnormalities and Variant t(9;22) at Diagnosis on Prognosis of Childhood Chronic Myelogenous Leukemia : The Experience of the International Registry for CML in Children and Adolescents (I-CML-Ped Study)

Author

Millot, Frédéric, primary, Guilhot, Joelle, additional, Suttorp, Meinolf, additional, Sedlacek, Pietr, additional, de Bont, Eveline S.J.M., additional, Li, Chi Kong, additional, Kalwak, Krzysztof, additional, Lausen, Birgitte, additional, Srdjana, Culic, additional, Dresse, Marie-Francoise, additional, Biondi, Andrea, additional, Baruchel, André, additional, and Brizard, Françoise, additional

Published
2014
Full Text
View/download PDF

8. The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study): Pronostic Consideration

Author

Millot, Frédéric, primary, Guilhot, Joelle, additional, Suttorp, Meinolf, additional, Sedlacek, Petr, additional, de Bont, Eveline S.J.M., additional, Li, Chi Kong, additional, Kalwak, Krzysztof, additional, Lausen, Birgitte, additional, Srdjana, Culic, additional, Dresse, Marie-Francoise, additional, Biondi, Andrea, additional, and Baruchel, Andre, additional

Published
2014
Full Text
View/download PDF

9. Identification of distinct protein Signatures Associated with genetic Abnormalities In Acute Lymphoblastic Leukemia

Author

Kuiper, Roland P., primary, Scheijen, Blanca, additional, Pastorczak, Agata, additional, van Reijmersdal, Simon V., additional, Thomas, Deborah A., additional, Zhang, Niangxiang, additional, Coombes, Kevin R., additional, Kantarjian, Hagop M., additional, Jabbour, Elias J., additional, De Bont, Eveline S.J.M, additional, van Leeuwen, Frank N., additional, and Kornblau, Steven M., additional

Published
2013
Full Text
View/download PDF

10. Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Author

Kaspers, Gertjan, primary, Mathot, Ron, additional, Ramnarain, Satianand, additional, Niewerth, Denise, additional, Locatelli, Franco, additional, De Bont, Eveline S.J.M, additional, Fagioli, Franca, additional, Rohrlich, Pierre, additional, von Stackelberg, Arend, additional, and Zwaan, Michel, additional

Published
2013
Full Text
View/download PDF

11. Overexpression of BRE in Pediatric MLL-Rearranged Acute Myeloid Leukemia Associated with t(9;11)(p22;q23).

Author

Balgobind, Brian, primary, Zwaan, C. Michel, additional, Arentsen-Peters, Susan T.C.J.M., additional, Reinhardt, Dirk, additional, Creutzig, Ursula, additional, de Haas, Valerie, additional, Kaspers, Gertjan J.L., additional, Cloos, Jacqueline, additional, de Bont, Eveline S.J.M, additional, Baruchel, Andre, additional, Stary, Jan, additional, Pieters, Rob, additional, and van den Heuvel-Eibrink, Marry M, additional

Published
2009
Full Text
View/download PDF

12. Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection.

Author

Bachas, Costa, primary, Schuurhuis, Gerrit-Jan, additional, Hollink, Iris H.I.M., additional, Goemans, Bianca F., additional, Reinhardt, Dirk, additional, Zwaan, Christian M, additional, van den Heuvel, Marry M., additional, de Bont, Eveline S.J.M, additional, Van Wering, Elisabeth R., additional, Kaspers, Gertjan, additional, and Cloos, Jacqueline, additional

Published
2009
Full Text
View/download PDF

13. Identification of Gene Expression Signatures Accurately Predicting Cytogenetic Subtypes in Pediatric Acute Myeloid Leukemia.

Author

Balgobind, Brian V, primary, van den Heuvel-Eibrink, Marry M, additional, Menezes, Renee X, additional, Reinhardt, Dirk, additional, Hollink, Iris H.I.M., additional, Arentsen-Peters, Susan T.J.C.M., additional, van Wering, Elisabeth R, additional, Kaspers, Gertjan, additional, Cloos, Jaqueline, additional, de Bont, Eveline S.J.M, additional, Baruchel, Andre, additional, Cayuela, Jean-Michel, additional, Stary, Jan, additional, Trka, Jan, additional, Beverloo, Berna, additional, Pieters, Rob, additional, Zwaan, Christian M, additional, and Den Boer, Monique L., additional

Published
2008
Full Text
View/download PDF

17. High IGSF4expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)

Author

Kuipers, Jenny E., Coenen, Eva A., Balgobind, Brian V., Stary, Jan, Baruchel, Andre, de Haas, Valerie, de Bont, Eveline S.J.M., Reinhardt, Dirk, Kaspers, Gertjan J.L., Cloos, Jacqueline, Danen-van Oorschot, Astrid A., den Boer, Monique L., Marschalek, Rolf, Meyer, Claus, Pieters, Rob, Zwaan, C. Michel, and van den Heuvel-Eibrink, Marry M.

Abstract

Pediatric mixed-lineage leukemia (MLL)–rearranged acute monoblastic leukemia with t(9;11)(p22;q23) has a favorable outcome compared with other MLL-rearranged AML. The biologic background for this difference remains unknown. Therefore, we compared gene expression profiles (GEPs; Affymetrix HGU133 + 2.0) of 26 t(9;11)(p22;q23) patients with 42 other MLL-rearranged AML patients to identify differentially expressed genes. IGSF4, a cell-cell adhesion molecule, was found to be highly expressed in t(9;11)(p22;q23) patients, which was confirmed by real-time quantitative polymerase chain reaction and Western blot. IGSF4expression within t(9;11)(p22;q23) patients was 4.9 times greater in French-American-British morphology classification (FAB)–M5 versus other FAB-types (P= .001). Methylation status investigation showed that high IGSF4-expressing t(9;11)(p22;q23) patients with FAB-M5 have no promoter hypermethylation, whereas all other cases do. Cell-line incubation with demethylating agent decitabine resulted in promoter demethylation and increased expression of IGSF4. Down-regulation of IGSF4by siRNA did not affect proliferation or drug sensitivity. In a cohort of 79 MLL-rearranged AML cases, we show significant better overall survival for cases with high IGSF4expression (5-year overall survival 0.70 vs 0.37, P= .03) In conclusion, we identified IGSF4overexpression to be discriminative for t(9;11)(p22;q23) patients with FAB-M5, regulated partially by promoter methylation and resulting in survival benefit.

Published
2011
Full Text
View/download PDF

18. High VEGFCexpression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia

Author

de Jonge, Hendrik J.M., Valk, Peter J.M., Veeger, Nic J.G.M., ter Elst, Arja, den Boer, Monique L., Cloos, Jacqueline, Haas, Valérie de, van den Heuvel-Eibrink, Marry M., Kaspers, Gertjan J.L., Zwaan, Christian M., Kamps, Willem A., Löwenberg, Bob, and de Bont, Eveline S.J.M.

Abstract

High VEGFCmRNA expression of acute myeloid leukemia (AML) blasts is related to increased in vitro and in vivo drug resistance. Prognostic significance of VEGFCon long-term outcome and its associated gene expression profiles remain to be defined. We studied effect of VEGFCon treatment outcome and investigated gene expression profiles associated with VEGFCusing microarray data of 525 adult and 100 pediatric patients with AML. High VEGFCexpression appeared strongly associated with reduced complete remission rate (P= .004), reduced overall and event-free survival (OS and EFS) in adult AML (P= .002 and P< .001, respectively). Multivariable analysis established high VEGFCas prognostic indicator independent of cytogenetic risk, FLT3-ITD, NPM1, CEBPA, age, and white blood cell count (P= .038 for OS; P= .006 for EFS). Also, in pediatric AML high VEGFCwas related to reduced OS (P= .041). A unique series of differentially expressed genes was identified that distinguished AML with high VEGFCfrom AML with low VEGFC, that is, 331 up-regulated genes (representative of proliferation, vascular endothelial growth factor receptor activity, signal transduction) and 44 down-regulated genes (eg, related to apoptosis) consistent with a role in enhanced chemoresistance. In conclusion, high VEGFCpredicts adverse long-term prognosis and provides prognostic information in addition to well-known prognostic factors.

Published
2010
Full Text
View/download PDF

19. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4AmRNA with prognostic significance

Author

de Jonge, Hendrik J.M., de Bont, Eveline S.J.M., Valk, Peter J.M., Schuringa, Jan Jacob, Kies, Marcel, Woolthuis, Carolien M., Delwel, Ruud, Veeger, Nic J.G.M., Vellenga, Edo, Löwenberg, Bob, and Huls, Gerwin

Abstract

Acute myeloid leukemia (AML) has a different clinical and biologic behavior in patients at older age. To gain further insight into the molecular differences, we examined a cohort of 525 adults to compare gene expression profiles of the one-third of youngest cases (n = 175; median age 31 years) with the one-third of oldest cases (n = 175; median age 59 years). This analysis revealed that 477 probe sets were up-regulated and 492 probe sets were down-regulated with increasing age at the significance level of P< .00001. After validation with 2 independent AML cohorts, the 969 differentially regulated probe sets on aging could be pointed to 41 probe sets, including the tumor-suppressor gene CDKN2A(encoding p16INK4A). In contrast to the induced p16INK4Aexpression that is associated with physiologic aging, p16INK4Ais down-regulated in AML samples of patients with increasing age. However, this was only noticed in the intermediate- and unfavorable-risk group and not in the favorable-risk group and the molecularly defined subset “NPM1mutant without FLT3-ITD.” Multivariate analysis revealed p16INK4A, besides cytogenetic risk groups, as an independent prognostic parameter for overall survival in older patients. We conclude that, in addition to altered clinical and biologic characteristics, AML presenting at older age shows different gene expression profiles.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results